Pathogen Specific Immunity in Patients With Sarcoidosis
NCT ID: NCT00217789
Last Updated: 2013-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
5 participants
OBSERVATIONAL
2004-07-31
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Since its initial description 125 years ago, sarcoidosis continues to be a "challenging" disease. Its etiology remains unknown. Discovering the etiology of sarcoidosis remains a major goal with important implications regarding treatment, predicting outcome, as well as determining approaches for preventive measures. Immunological responses and granulomatous tissue formation characterizing sarcoidosis are similar to those observed in a variety of infectious diseases. However, the nature of the specific antigen(s), which putatively trigger the inflammatory response in sarcoidosis, remains elusive. Occurrence of sarcoidosis in spatially related clusters, and household and health care settings strongly support person-to-person transmission of an infectious agent as one of the potential causes of this disease. Sarcoidosis has been associated with a variety of infectious agents, none of which can be cultured. Propionibacterium acnes (P. acnes) and M.tuberculosis (Mtb) are the most commonly identifiable infectious pathogens by PCR-based methods and considered to be associated with the development of this disease. Immunological studies in sarcoidosis have focused largely on the assessment of constitutive, immune responses and the description of the phenotypes of blood and lung cells in patients and control subjects.
DESIGN NARRATIVE:
This study will utilize memory immune responses as search tools for the 'immunological imprints' from P. acnes or Mtb exposure. Peripheral blood mononuclear cells and bronchoalveolar cells will be compared from patients with stage II and/or stage III sarcoidosis and from healthy control subjects. Investigators will use ELISPOT assay to study: (1) frequencies of pathogen-specific interferon-7 and interleukin-10-producing cells, and (2) utilizing P. acnes- or Mtb-infected autologous monocytes and alveolar macrophages as target cell frequencies of pathogen-specific granzyme B-releasing cytotoxic T lymphocytes and natural killer cells. Finally, investigators will test the feasibility of identifying by DNA micro array, pathogen specific, transcriptional host gene expression profiles in P. acnes- and Mtb-stimulated blood cells from healthy control subjects and patients with active sarcoidosis and to compare these with gene expression profiles from autologous, unstimulated in situ lung cells. The studies will address the role of P. acnes and Mtb in the etiology of sarcoidosis and will also serve as a basis or model for future work involving other possible infectious or non-infectious pathogens/antigens for the development of sarcoidosis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bronchoalveolar Lavage and Venipuncture
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No prior corticosteroid or immune suppressive or immune modulating therapies
* No clinical and radiographic signs and symptoms of respiratory or other chronic or systemic illness
Exclusion Criteria
* Unwilling or unable to comply with all study requirements
* History of upper or lower respiratory tract infection within 1 month of study entry
* History of major occupational or microbial exposures known to be associated with granulomatous inflammatory responses
* Positive HIV-1 serology
* Severe psychiatric disease
* Cough-induced syncope
* History of massive hemoptysis or history of pneumothorax, tuberculosis, and immunosuppressive therapies
* Presence of any chronic medical condition requiring daily medication
* Gingivitis or other infectious processes in the oral cavity
* Positive skin test to purified protein derivative (tuberculin)
* Hemoglobin level less than 10g/dl
* Illicit drug use or history of cigarette smoking within 1 year prior to study entry
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
University of Medicine and Dentistry of New Jersey
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stephan Schwander, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Medicine and Dentistry of New Jersey
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Medicine and Dentistry of New Jersey
Newark, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.